AGEN AGENUS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$3.48

Period return

-0.69 (-16.55%)

Volume

863.3K

2026-06-01O $3.5 H $3.52 L $3.33 C $3.48MA5 $3.42MA20 $3.49MA60 $3.69MA120 $3.52

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2025. 09. 10.LowBUY9 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 08. 28.LowBUY9 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 06. 04.LowHOLD12 months ago
Baird: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $15.5 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Sector

2025. 06. 04.MediumBUY12 months ago

HC Wainwright & Co.: Buy